

acg2usa.ST25



00270

PATENT TRADEMARK OFFICE

## SEQUENCE LISTING

9

<110> Gevas, Philip  
Grimes, Stephen  
Karr, Stephen  
Michaeli, Dov  
Watson, Susan

<120> Prevention and Treatment of Hypergastrinemia

<130> ACG2USA

<140> US 09/700,329  
<141> 2001-02-08

<150> PCT/US99/10751  
<151> 1999-05-14

<150> 60/085,714  
<151> 1998-05-15

<160> 9

<170> PatentIn version 3.0

<210> 1  
<211> 9  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 1

Glu Gly Pro Trp Leu Glu Glu Glu Glu  
1 5

<210> 2  
<211> 12  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 2

Glu Leu Gly Pro Gln Gly Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 3  
<211> 7  
<212> PRT  
<213> human or synthetic peptide

<400> 3

Ser Ser Pro Pro Pro Pro Cys  
1 5

<210> 4  
<211> 7  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> AMIDATION

<400> 4

Glu Ala Tyr Gly Trp Met Asp  
1 5

<210> 5  
<211> 12  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 5

Glu Gly Pro Trp Leu Glu Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 6  
<211> 11  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 6

Glu Gly Pro Trp Leu Arg Pro Pro Pro Pro Cys  
1 5 10

acg2usa.ST25

<210> 7  
<211> 10  
<212> PRT  
<213> human gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 7

Glu Gly Pro Trp Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 8  
<211> 12  
<212> PRT  
<213> rat gastrin peptide

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 8

Glu Arg Pro Pro Leu Glu Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 9  
<211> 15  
<212> PRT  
<213> human gastrin peptide

<400> 9

Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu Pro Pro Pro Pro Cys  
1 5 10 15



00270

PATENT TRADEMARK OFFICE

## Exhibit A

COPY

## PATENT

Serial No. \_\_\_\_\_ Doc. No. 00270 Atty/Sec. MS/ldh Date 11-14-00Inventor J. Gervais et al. Client ACC.Title Prevention and treatment of hypergastrinemia

The following has been received in the U.S. Patent and Trademark Office on the date stamped hereon:

☒ 22 pp. Spec., 24 Claims, 1 pg. Abstract ☐ pp. Amendment: OA dtd \_\_\_\_\_

☒ 3 pp. Declaration/Power of Attorney ☐ pp. Response: OA dtd \_\_\_\_\_

☒ 1 pp. Verified Statement (Small Entry) ☒ 2 pp. Transmittal Letter

☐ shts. Informal Drawings ☐ Issue Fee

☒ 12 shts. Formal Drawings (Figs. 1-12) ☐ Notice of Appeal & Fee

☐ pp. Assignment ☒ Check # 15703 for \$ 345.00
☒ 2 pp. Preliminary Amendment ☒ Check # 7504 for \$ 290.00
☐ pp. Extension of Time ☒ 7 pg. Second Prel. Am.

☐ pp. Information Disclosure Statement ☒ 1 pg. Transmittal Letter

☐ with PTO-1449 and \_\_\_\_\_ references ☒ 3 pg. Sec. List ☒ 1 pg. Statement

☒ 3 pg. P. Letter

The Patent and Trademark Office is respectfully requested to place its stamp on this postal card and place it in the outgoing mail.

Respectfully,

HOWSON AND HOWSON

Express Mail 120

EX 990703206US

MEYS

09/700329

525 Rec'd PCT/PTO 14 NOV 2000

acg2usa.ST25

*copies*  
**Exhibit B**

## SEQUENCE LISTING

**COPY**

<110> Gevas, Philip  
Grimes, Stephen  
Karr, Stephen  
Michaeli, Dov  
Watson, Susan

<120> Prevention and Treatment of Hypergastrinemia

<130> ACG2USA

<150> PCT/US99/10751

<151> 1999-05-14

<150> 60/085,714

<151> 1998-05-15

<160> 9

<170> PatentIn version 3.0

<210> 1

<211> 9

<212> PRT

<213> human

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> pyroglutamic acid

<400> 1

Glu Gly Pro Trp Leu Glu Glu Glu Glu  
1 5

<210> 2

<211> 12

<212> PRT

<213> human

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> pyroglutamic acid

<400> 2



00270

PATENT TRADEMARK OFFICE



acg2usa.ST25

Glu Leu Gly Pro Gln Gly Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 3  
<211> 7  
<212> PRT  
<213> human or synthetic peptide

<400> 3

Ser Ser Pro Pro Pro Pro Cys  
1 5

<210> 4  
<211> 7  
<212> PRT  
<213> human or synthetic peptide

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> AMIDATION

<400> 4

Glu Ala Tyr Gly Trp Met Asp  
1 5

<210> 5  
<211> 12  
<212> PRT  
<213> human

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> pyroglutamic acid

<400> 5

Glu Gly Pro Trp Leu Glu Arg Pro Pro Pro Pro Cys  
1 5 10

<210> 6  
<211> 11  
<212> PRT  
<213> human

<220>

acg2usa.ST25

<221> MOD\_RES  
 <222> (1)..(1)  
 <223> pyroglutamic acid

<400> 6

Glu Gly Pro Trp Leu Arg Pro Pro Pro Pro Cys  
 1 " 5 10

<210> 7  
 <211> 10  
 <212> PRT  
 <213> human

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> pyroglutamic acid

<400> 7

Glu Gly Pro Trp Arg Pro Pro Pro Pro Cys  
 1 5 10

<210> 8  
 <211> 12  
 <212> PRT  
 <213> rat

<220>  
 <221> MOD\_RES  
 <222> (1)..(1)  
 <223> pyroglutamic acid

<400> 8

Glu Arg Pro Pro Leu Glu Arg Pro Pro Pro Pro Cys  
 1 5 10

<210> 9  
 <211> 15  
 <212> PRT  
 <213> human

<400> 9

Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu Pro Pro Pro Pro Cys  
 1 5 10 15